Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
- Resource Type
- journal article
- Authors
- Eisen, Tim; Frangou, Eleni; Oza, Bhavna; Ritchie, Alastair W.S.; Smith, Benjamin; Kaplan, Rick; Davis, Ian D.; Stockler, Martin R.; Albiges, Laurence; Escudier, Bernard; Larkin, James; Bex, Axel; Joniau, Steven; Hancock, Barry; Hermann, Gregers G.; Bellmunt, Joaquim; Hodgkinson, Elizabeth; Stewart, Grant D.; Barber, Jim; Brown, Janet
- Source
- Journal of Clinical Oncology; 12/1/2020, Vol. 38 Issue 34, p4064-4075, 25p
- Subject
- Language
- ISSN
- 0732183X